ValuEngine upgraded shares of Molecular Templates (NASDAQ:MTEM) from a sell rating to a hold rating in a research report released on Monday morning.
Several other analysts have also recently issued reports on the stock. BidaskClub raised shares of Molecular Templates from a buy rating to a strong-buy rating in a research note on Friday, December 22nd. Zacks Investment Research raised shares of Molecular Templates from a sell rating to a hold rating in a research note on Wednesday, January 17th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $5.20.
Shares of NASDAQ MTEM opened at $8.69 on Monday. Molecular Templates has a 52-week low of $3.85 and a 52-week high of $13.25. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02.
Several hedge funds and other institutional investors have recently made changes to their positions in MTEM. OxFORD Asset Management LLP purchased a new stake in shares of Molecular Templates during the 3rd quarter valued at $140,000. Alps Advisors Inc. purchased a new stake in shares of Molecular Templates during the 4th quarter valued at $298,000. Wells Fargo & Company MN grew its stake in shares of Molecular Templates by 1,744.7% during the 4th quarter. Wells Fargo & Company MN now owns 10,035 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 9,491 shares during the period. BlueCrest Capital Management Ltd purchased a new stake in shares of Molecular Templates during the 4th quarter valued at $157,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Molecular Templates during the 4th quarter valued at $131,000. 16.19% of the stock is owned by institutional investors.
Molecular Templates Company Profile
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.